Date:1/24/2012

p>  

 

 

 

 

 

 

 

 

 

 

  

 

 

 

 

 

 

 

 

 

 

  

 

 

 

 

 

 

 

 

 

 

  

 

 

 

 

 

 

 

 

 

 

  

 

 

 

 

 

 

 

 

 

 

  

 

 

REPORTED SALES vs. PRIOR PERIOD ($MM)  FOURTH QUARTER TWELVE MONTHS 

 

 % Change 

 

 % Change 20112010ReportedOperational ⁽¹⁾Currency 20112010ReportedOperational ⁽¹⁾CurrencyPHARMACEUTICAL SEGMENT  ^{(2) (4)} 

 

 

 

 

 

 

 

 

 

 ACIPHEX/PARIET

 

 

 

 

 

 

 

 

 

 

 US110119-7.6%

-7.6%

-

 414475-12.8%

-12.8%

-Intl1441338.3%

8.7%

-0.4%

 5615315.6%

0.0%

5.6%WW2542520.8%

1.0%

-0.2%

 9751,006-3.1%

-6.1%

3.0%CONCERTA/METHYLPHENIDATE

 

'/>"/>

SOURCE Johnson & Johnson Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33
Related medicine technology :

1. Johnson & Johnson to Provide Webcast Presentation of Tapentadol Phase 3 Clinical Data Presented at American Pain Societys Annual Meeting
2. Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Announces FDA Filings for Paliperidone Palmitate and INVEGA(R)
3. Simbionix and Johnson & Johnson LLC Announce Distribution Agreement at Russia and the CIS Countries
4. Johnson & Johnson Announces Support for Kohl-Grassley Physician Payments Sunshine Act of 2009
5. Boston Scientific and Johnson & Johnson Announce Settlement of Patent Disputes
6. Palomar to Commercialize FDA Cleared Over-The-Counter Home Use Wrinkle Treatment Laser Device Without Johnson & Johnson
7. U.S. Files Suit Against Johnson & Johnson For Paying Kickbacks to Nations Largest Nursing Home Pharmacy
8. EF Johnson Technologies Announces Third Quarter Results
9. Emerging Agents from Theravance/Astellas, Johnson & Johnson/Basilea and Forest/Astrazeneca/Takeda Will Drive Modest Growth in the MRSA Drug Market Through 2018
10. Johnson & Johnson to Participate in the 30th Annual Cowen and Company Health Care Conference
11. Two Johnson & Johnson Subsidiaries to Pay Over $81 Million to Resolve Allegations of Off-Label Promotion of Topamax